Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125252681 | 12525268 | 1 | I | 20160623 | 20160704 | 20160704 | EXP | AR-PFIZER INC-2016317565 | PFIZER | 55.00 | YR | F | Y | 0.00000 | 20160704 | CN | AR | AR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125252681 | 12525268 | 1 | PS | SUTENT | SUNITINIB MALATE | 1 | 37.5 MG, CYCLIC (4/2 SCHEME) | N | 21938 | 37.5 | MG | CAPSULE, HARD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125252681 | 12525268 | 1 | Metastatic renal cell carcinoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125252681 | 12525268 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125252681 | 12525268 | Blindness | |
| 125252681 | 12525268 | Disease progression | |
| 125252681 | 12525268 | Dizziness | |
| 125252681 | 12525268 | Headache | |
| 125252681 | 12525268 | Metastatic renal cell carcinoma | |
| 125252681 | 12525268 | Monoplegia | |
| 125252681 | 12525268 | Noninfective encephalitis | |
| 125252681 | 12525268 | Speech disorder |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125252681 | 12525268 | 1 | 20120911 | 20160415 | 0 |